FY2025 · ended Dec 31, 2025 · Revenue $82.03M, -46.1% YoY · Filed Mar 3, 2026
Arcturus Therapeutics Holdings Inc. (ARCT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $82.0 million and a net loss of $65.8 million. Free cash flow was -$74.5 million. As of Sep 30, 2026 it held $184.8 million in cash and investments and $21.9 million in total debt.
Revenue (TTM)
$30.51M
-68.7% vs year-ago TTM
Net income (TTM)
$-87.24M
-30.8% vs year-ago TTM
Operating cash flow (TTM)
$-62.48M
-7.1% vs year-ago TTM
Free cash flow (TTM)
$-62.52M
-6.6% vs year-ago TTM
EPS (TTM)
$-3.08
-25.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.42M
+4.8% vs prior year
Net cash
$162.95M
as of Sep 30, 2026
Operating margin
-311.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1768224
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M |
| Net income | -$65.8M | -$80.9M | -$29.7M | $9.3M | -$203.7M |
| Diluted EPS | -$2.40 | -$3.00 | -$1.12 | $0.35 | — |
| Operating cash flow | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M |
| Stockholders' equity | $214.0M | $241.0M | $278.5M | $270.3M | $228.2M |
| Cash and investments | $230.9M | $237.0M | $292.0M | $391.9M | $370.5M |
| Total debt | $25.0M | $28.6M | $30.2M | $94.8M | $69.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 25, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 416 Arcturus Therapeutics Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.